iCAD Inc ( (ICAD) ) has released its Q3 earnings. Here is a breakdown of the information iCAD Inc presented to its investors.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
iCAD, Inc., based in Nashua, N.H., is a global leader in AI-powered breast health solutions aimed at improving cancer detection and patient outcomes. The company leverages artificial intelligence to provide advanced mammography analysis for diagnostic purposes.
In its latest earnings report for the third quarter of 2024, iCAD, Inc. highlighted a 10% year-over-year increase in Annual Recurring Revenue (ARR), which now stands at $9.3 million. The company also reported a 4% rise in total revenues, reaching $4.2 million. The period saw significant strategic achievements, including the FDA clearance of ProFound Detection v4.0, which enhances cancer detection capabilities.
Key financial metrics revealed an 86% gross profit margin, maintaining consistency with the previous year. iCAD noted an increase in operating expenses, which rose by 19% year-over-year, contributing to a GAAP net loss of $1.8 million for the quarter. Despite these challenges, the company achieved substantial growth in product revenue, up 14.1%, while services revenue saw a decline of 8.9%.
iCAD’s management remains optimistic about the company’s future, focusing on expanding its market reach and enhancing its product offerings. The recent regulatory clearances in international markets and the anticipated demand due to new U.S. regulations on breast density reporting are expected to drive future growth and strengthen its market leadership in AI-powered breast cancer detection.
